R. LaDuane Clifton
CFO, Secretary & Treasurer at Zevra Therapeutics
R and D expenses were 3,300,000.0 for Q1 twenty twenty five, which was a decrease of 9,000,000 compared to Q1 twenty twenty four, due primarily to a decrease in third party cost upon completion of the KP1077 Phase II trial combined with a decrease in personnel related costs. SG and A expenses were 19,500,000.0 for Q1 twenty twenty five, which was an increase of $9,600,000 Period over period increase in SG and A expenses was primarily related to an increase in personnel related costs, professional fees and other expenses associated with our commercial, medical and launch activities. Net loss for the first quarter of twenty twenty five was $3,100,000 or $06 per basic and diluted share compared to $16,600,000 or $0.40 per basic and diluted share for the same quarter a year ago. As of 03/31/2025, total cash, cash equivalents and investments were $68,700,000 which was a decrease of $6,800,000 compared to 12/31/2024. Combined with the net proceeds of 148,300,000.0 from the sale of the PRV received just after the end of the quarter on April 1, cash, cash equivalents and investments would be $217,000,000 Total debt was approximately 60,000,000 As mentioned earlier, adding the non dilutive capital from the PRV sale has further enhanced our financial flexibility to support our strategic priorities, which includes executing on the commercial launches of Myplifa and Opruva and supporting our ongoing Phase three trial for saliprolol.